- Home
- SABR vs DAWN Comparison
SABR vs DAWN Comparison
Compare SABR & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SABR | DAWN |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 627.9M | 624.8M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SABR | DAWN |
|---|---|---|
| Price | $1.46 | $9.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $4.12 | ★ $26.56 |
| AVG Volume (30 Days) | ★ 6.1M | 3.1M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.41 | N/A |
| Revenue | ★ $3,034,040,000.00 | $133,672,000.00 |
| Revenue This Year | N/A | $15.51 |
| Revenue Next Year | $3.88 | $49.99 |
| P/E Ratio | $1.06 | ★ N/A |
| Revenue Growth | 8.86 | ★ 31.11 |
| 52 Week Low | $1.46 | $5.64 |
| 52 Week High | $4.63 | $13.53 |
Technical Indicators
Market Signals| Indicator | SABR | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 33.50 | 59.54 |
| Support Level | $1.47 | $8.13 |
| Resistance Level | $1.56 | $10.47 |
| Average True Range (ATR) | 0.08 | 0.63 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 4.26 | 67.51 |
Price Performance
Historical ComparisonAbout SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2024 revenue, split between distribution (79% of segment sales) and airline IT solutions (21%) revenue. The company sold its growing hotel IT solutions division (9% of revenue) to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.